Angelini Ventures
Laigo Bio raises €11.5M to transform targeted protein degradation in oncology and autoimmunity
We are excited to announce Angelini Ventures' investment in Laigo Bio, an innovative Dutch biotech company developing first-in-class solutions for selective protein degradation in oncology and autoimmune diseases.
The €11.5M seed round, co-led by Kurma Partners and Curie Capital, demonstrates the caliber of breakthrough science emerging from Argobio, the venture studio we co-founded and actively support in Paris.
This marks our second Argobio-backed investment, underscoring our strategic approach: while our core focus remains on Series A and Series B opportunities, partnerships with early-stage venture studios allow us to identify and nurture transformative science from its inception.
Lola Buono, our Senior Associate and investment lead on this deal, will join Laigo Bio's board as an observer, positioning us to support the company's scaling journey.
We are thrilled to support Laigo Bio on its journey to redefine what's possible in targeted protein degradation. Laigo Bio's platform brings a novel way to degrade membrane-bound drivers of oncology and autoimmune diseases. At Angelini Ventures, we look for science that can shift paradigms rather than refine them, and Laigo Bio stands out for the clarity of its vision and the strength of its early data. This investment also reflects our continuous support to the consistently excellent quality of ArgoBio's spinouts, as well as our commitment to helping bold European science scale globally.
Lola Buono,
To learn more about Laigo Bio's technology and the full details of this financing round, download the press release.